It has shown clinical value in the initial staging of newly diagnosed high-risk prostate cancer, localization of disease sites in patients with biochemical recurrence, and identification of appropriate patients for PSMA-targeted radiopharmaceutical therapy (1–4). The gene discussed is FOLH1; the disease is prostate carcinoma.